1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. BRAZIL PAIN MANAGEMENT DRUGS MARKET BY DRUG TYPE
5.1. Introduction
5.2. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
5.3. Corticosteroids
5.4. Acetaminophen
5.5. Opioid
5.5.1. Strong Opioid
5.5.2. Weak Opioid
5.6. Antidepressants
5.7. Anticonvulsant Drugs
5.8. Others
6. BRAZIL PAIN MANAGEMENT DRUGS MARKET BY DISTRIBUTION CHANNEL
6.1. Introduction
6.2. Hospital Pharmacies
6.3. Retail Pharmacies
6.4. Online Pharmacies
7. BRAZIL PAIN MANAGEMENT DRUGS MARKET BY INDICATION
7.1. Introduction
7.2. Cancer
7.3. Rheumatoid Arthritis
7.4. Chronic Back Pain
7.5. Post-Operative Pain
7.6. Others
8. BRAZIL PAIN MANAGEMENT DRUGS MARKET BY STATE
8.1. Introduction
8.2. São Paulo
8.2.1. By Drug Type
8.2.2. By Distribution Channel
8.2.3. By Indication
8.3. Minas Gerais
8.3.1. By Drug Type
8.3.2. By Distribution Channel
8.3.3. By Indication
8.4. Rio de Janeiro
8.4.1. By Drug Type
8.4.2. By Distribution Channel
8.4.3. By Indication
8.5. Parana
8.5.1. By Drug Type
8.5.2. By Distribution Channel
8.5.3. By Indication
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. Novartis Pharmaceuticals Corporation (Novartis AG)
10.2. Eurofarma Laboratories
10.3. EMS Pharma S.A.
10.4. Pfizer Inc.
10.5. Abbott Laboratories
10.6. Johnson & Johnson
10.7. Sanofi
10.8. Medtronic
11. APPENDIX
11.1. Currency
11.2. Assumptions
11.3. Base and Forecast Years Timeline
11.4. Key benefits for the stakeholders
11.5. Research Methodology
11.6. Abbreviations
LIST OF FIGURES
LIST OF TABLES